Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- NOK -16.2%, UCTT -11.3%, NTRI -10.8%, TAL -10.8%, CELG -9.8%, MLNX-8.6%, ESND -8%, VAR -6.6%, OII -6.5%, ORLY -6.3%, ONCS -6.1%, JAKK-5.9%, XLNX -5.3%, UHS -5.2%, BCS -5.2%, ALKS -5%, RVLT -5%, POT-4.8%, NOW -4.5%, DLB -4%, SSNC -3.9%, BSX -3.7%, CA -3.5%, MC -3.5%,TSCO -3.3%, HLI -3.2% (also announces secondary offering of class A common stock by selling stockholders), CDE -2.9%, NTGR -2.8%, IART-2.8%, MMLP -2.7%, PKG -2.7%, AMGN -2.6%, DNKN -2.5%, KKR -2.5%,BUD -2.4%, FAF -2.4%, ABMD -2.3%, DB -2.2%, GNC -2.1%, ALLE -1.9%,MDP -1.9%, WPG -1.6%, BMY -1.6%, STO -1.4%, CMO -1%, VC -1%, RJF-0.9%, VRTX -0.9%, ABX -0.9%, PSA -0.8%, ICLR -0.8%
Other news:
- ATOS -24.5% (proposes public offering of common stock)
- IDRA -21.7% (prices 33,333,334 shares at $1.50)
- VBIV -6% (commenced an underwritten public offering and a registered direct offering of its common shares )
- HCM -4.6% (prices 9,886,792 ADSs at $26.50 per share)
- CSX -4.5% (light volume; CSX authorized $1.5 billion in share repurchases; is postponing its scheduled October 30th Investor Conference to a later date)
Analyst comments:
- PCRX -5.8% (downgraded to Sell from Neutral at Janney)
- PTCT -5.4% (downgraded to Underperform from Neutral at BofA/Merrill)
- TRVG -1.8% (downgraded to Underperform from Neutral at BofA/Merrill; downgraded to Neutral from Buy at Guggenheim)
- WWD -1.7% (downgraded to Perform from Outperform at Oppenheimer)
- GSK -1% (downgraded to Neutral from Buy at BofA/Merrill)
- LB -1% (downgraded to Neutral from Buy at Buckingham Research)